【24h】

Pneumatic displacement of submacular hemorrhage with or without tissue plasminogen activator.

机译:伴或不伴组织纤溶酶原激活剂的黄斑下出血的气动置换。

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE: To assess the efficacy and complications of intravitreal injection of sulfur hexafluoride (SF(6)) gas with/without tissue plasminogen activator (tPA) for displacing submacular hemorrhage. METHODS: The medical records of 53 eyes that underwent pneumatic displacement for submacular hemorrhage were reviewed retrospectively. Submacular hemorrhage was related to exudative age-related macular degeneration (AMD) in 39 eyes and ruptured retinal arterial macroaneurysms in 14 eyes, and treated with intravitreal injection of SF(6) gas with or without tPA. RESULTS: Compared with preoperatively (mean follow-up, 18.4 months), the final visual acuity (VA) improved by 0.3 or more logMAR unit in 34 eyes (64.2%), stabilized within 0.3 logMAR in 15 eyes (28.3%), and deteriorated in four eyes (7.5%). In eyes with AMD, hemorrhage including vitreous hemorrhage recurred in eight (22.2%) of 36 eyes treated with tPA and one (33.3%) of three eyes not treated with tPA. In eyes with macroaneurysms, hemorrhage recurred in four (100%) of four eyes treated with tPA and in one (10.0%) of ten eyes without tPA (p < 0.005). Eight eyes underwent vitrectomy for recurrent hemorrhage. During follow-up, photodynamic therapy or intravitreal ranibizumab or pegaptanib was administered in 16 (41.0%) of 39 eyes with AMD. Postoperative ocular hypertension persisting over 3 days was not observed. CONCLUSIONS: Intravitreal SF(6) gas plus tPA may be well-accepted, with good visual outcomes and no remarkable complications for treating submacular hemorrhage secondary to AMD. tPA is not recommended for ruptured retinal arterial macroaneurysms, because of a higher incidence of subsequent vitreous hemorrhage. Pneumatic displacement of submacular hemorrhage without tPA may provide good visual outcomes with less re-bleeding.
机译:目的:评估玻璃体内注射六氟化硫(SF(6))气体与/不具有组织纤溶酶原激活剂(tPA)取代黄斑下出血的疗效和并发症。方法:回顾性分析53例因黄斑下出血行气管置换术的眼睛的病历。黄斑下出血与39眼渗出性年龄相关性黄斑变性(AMD)和14眼破裂性视网膜动脉大动脉瘤有关,并通过玻璃体内注射SF(6)气体进行治疗,伴或不伴tPA。结果:与术前相比(平均随访18.4个月),34眼(64.2%)的最终视力(VA)提高了0.3或更多logMAR单位,15眼(28.3%)的稳定在0.3 logMAR内,并且四只眼恶化(7.5%)。在患有AMD的眼中,用tPA治疗的36眼中有8例(22.2%)复发了包括玻璃体出血的出血,而未用tPA治疗的3眼中有1例(33.3%)复发。在患有大动脉瘤的眼中,使用tPA治疗的四只眼中有四只(100%)发生出血,而未使用tPA的十只眼中有一只(10.0%)复发(p <0.005)。八只眼睛接受了玻璃体切除术,以防再次出血。在随访过程中,对39眼AMD中的16眼(占41.0%)进行了光动力疗法或玻璃体内兰尼单抗或培加他尼治疗。没有观察到术后高眼压持续超过3天。结论:玻璃体内SF(6)气体加tPA可能是公认的,具有良好的视觉效果,且无明显并发症可治疗AMD继发的黄斑下出血。不建议将tPA用于破裂的视网膜动脉大动脉瘤,因为随后发生玻璃体出血的可能性更高。没有tPA的黄斑下出血的气动置换可以提供良好的视觉效果,减少再出血。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号